Krystexxa (pegloticase) / Amgen 
Welcome,         Profile    Billing    Logout  
 16 Diseases   4 Trials   4 Trials   584 News 


«1234567»
  • ||||||||||  Revolixys (anivamersen/pegnivacogin) / AbbVie, Omontys (peginesatide) / Affymax, Krystexxa (pegloticase) / Horizon Therapeutics
    ROS-scavenging  (Regency Ballroom C (Hyatt Regency Indianapolis)) -  Feb 14, 2023 - Abstract #ACSSp2023ACS_SP_12755;    
    B. Unlike with PEG, no anti-polymer antibodies were formed in PTGG/OVA treated mice.
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Trial completion date, Trial primary completion date:  Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome (clinicaltrials.gov) -  Dec 8, 2022   
    P4,  N=10, Recruiting, 
    Pegloticase + methotrexate co-therapy resulted in sustained SU-lowering with meaningful improvements in clinical measures, urate burden, and patient-reported outcomes. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Krystexxa (pegloticase) / Horizon Therapeutics
    eGFR Changes in Uncontrolled Gout Patients Undergoing Pegloticase Plus Methotrexate Co-Therapy (Exhibit Hall, Orange County Convention Center, West Building) -  Oct 13, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_3294;    
    Conclusion These limited data show similar pegloticase+MTX urate-lowering efficacy in CKD and non-CKD pts. Most CKD pts had renal stability/improvement during therapy, but further study is needed.
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Enrollment open:  Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome (clinicaltrials.gov) -  Sep 30, 2022   
    P4,  N=10, Recruiting, 
    Conclusion Pegloticase 8 mg IV q2w with standard of care immunosuppressants in transplant patients resulted in a high SU responder rate and improved pegloticase exposure. Active, not recruiting --> Recruiting
  • ||||||||||  Krystexxa (pegloticase) / Horizon Therapeutics
    eGFR Changes in Uncontrolled Gout Patients Undergoing Pegloticase + Methotrexate Co-therapy (Virtual Poster Hall) -  Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_2991;    
    These limited data show similar pegloticase+MTX urate-lowering efficacy in CKD and non-CKD patients. Additionally, no new safety signals were identified with the majority of CKD patients showing eGFR stability or improvement during therapy.
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Enrollment closed, Trial completion date, Trial primary completion date:  Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome (clinicaltrials.gov) -  Sep 7, 2022   
    P4,  N=10, Active, not recruiting, 
    These findings verify higher treatment response rate, lower IR incidence, and lower immunogenicity when pegloticase is co-administered with MTX. Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Sep 2022 --> Dec 2022
  • ||||||||||  Krystexxa (pegloticase) / Horizon Therapeutics
    Review, Journal:  A glance into the future of gout. (Pubmed Central) -  Aug 6, 2022   
    Overall, the single change that will most impact gout management is greater uptake of international rheumatology society recommendations. Innovative strategies, such as nurse-led interventions based on these recommendations have recently demonstrated treatment success for people with gout.
  • ||||||||||  Krystexxa (pegloticase) / Horizon Therapeutics
    CLINICAL OUTCOMES AND HEALTHCARE RESOURCE UTILIZATION OF UNCONTROLLED GOUT PRIOR TO PEGLOTICASE THERAPY () -  May 24, 2022 - Abstract #EULAR2022EULAR_3985;    
    Overall, these data demonstrate the progressive nature of UG as confirmed by significant increases in gout-related conditions and healthcare resource utilization prior to pegloticase initiation. Further research is needed on healthcare resource utilization among patients with UG post-pegloticase use.
  • ||||||||||  Krystexxa (pegloticase) / Horizon Therapeutics
    PEGLOTICASE USE IN RENAL TRANSPLANT RECIPIENTS WITH GOUT: AN INSURANCE CLAIMS STUDY () -  May 24, 2022 - Abstract #EULAR2022EULAR_3976;    
    7 Real world data from KT patients support the hypothesis that transplant immunosuppression may allow more patients to receive a longer course of pegloticase therapy, presumably via anti-drug antibody attenuation. This is of particular importance for this vulnerable patient group that is at a high risk for developing uncontrolled gout.
  • ||||||||||  Krystexxa (pegloticase) / Horizon Therapeutics
    REAL-WORLD REPORTING OF GOUT FLARES IN UNCONTROLLED GOUT PATIENTS CO-TREATED WITH PEGLOTICASE AND METHOTREXATE () -  May 24, 2022 - Abstract #EULAR2022EULAR_3975;    
    Consistent with clinical trials, 2,3 flare rate was highest during the first 4 weeks of pegloticase treatment, progressively decreasing over time. Interestingly, these data suggest that patients who experience gout flares on pegloticase may have more obesity and a higher comorbidity burden than those who do not experience flares.
  • ||||||||||  Krystexxa (pegloticase) / Horizon Therapeutics
    Pegloticase Use in Renal Transplant Recipients with Gout: Findings from an Insurance Claims Database Study (Hynes Halls C & D: Board No. A160) -  May 20, 2022 - Abstract #ATC2022ATC_3228;    
    These findings are consistent with other reports of immunomodulation with pegloticase. This study showed a higher median number of pegloticase infusions than reported in prior claims-based studies of non-KT patients.7 Real world data from KT patients support the hypothesis that transplant immunosuppression can prevent the development of anti-drug antibodies to improve the rate of complete response to pegloticase in this vulnerable patient group that has a high risk for uncontrolled gout.
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Trial completion:  MIRROR RCT: Study of KRYSTEXXA (clinicaltrials.gov) -  May 16, 2022   
    P4,  N=152, Completed, 
    This study showed a higher median number of pegloticase infusions than reported in prior claims-based studies of non-KT patients.7 Real world data from KT patients support the hypothesis that transplant immunosuppression can prevent the development of anti-drug antibodies to improve the rate of complete response to pegloticase in this vulnerable patient group that has a high risk for uncontrolled gout. Active, not recruiting --> Completed
  • ||||||||||  Krystexxa (pegloticase) / Amgen
    Enrollment change, Trial completion date, Trial primary completion date:  A Phase 4, Open-label Study of KRYSTEXXA (clinicaltrials.gov) -  May 16, 2022   
    P4,  N=40, Recruiting, 
    Active, not recruiting --> Completed N=30 --> 40 | Trial completion date: Jan 2023 --> Oct 2023 | Trial primary completion date: Oct 2022 --> Aug 2023